Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 0457

Next Previous
Drug Profile

MEDI 0457

Alternative Names: INO-3112; INO-9012/VGX-3100; MEDI-0457; VGX-3100 plus IL-12; VGX-3100/INO-9012

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer AstraZeneca; Inovio Pharmaceuticals; University of Pennsylvania; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer; Head and neck cancer
  • Phase I/II Cervical cancer
  • No development reported Oropharyngeal cancer

Most Recent Events

  • 01 Mar 2023 Efficacy data from a phase Ib/IIa trial in Head and neck cancer released by Inovio Pharmaceuticals
  • 27 Sep 2022 No development reported - Phase-II for Oropharyngeal cancer (Combination therapy, Adjuvant therapy) in USA (IM)
  • 04 Jun 2021 Efficacy and adverse events data from a phase II trial in Cancers associated with Human Papilloma Virus (HPV) presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top